The expiration of the TRIPS waiver is just one aspect of a broader set of challenges that the industry will need to address.

Bangladesh's transition out of the Least Developed Countries (LDC) bracket to a developing nation will bring several challenges for the pharmaceutical industry, sector insiders fear.

Highlights: Bangladesh produces only 41 of 400 needed APIs, relying on imports for 80% Pharma market is worth $2.92b, ...